Scilex Holding (SCLX) Convertible Debt (2021 - 2022)
Scilex Holding (SCLX) posted quarterly Convertible Debt of $2.0 million for Q3 2022, little changed quarter-over-quarter from $2.0 million in Q2 2022.
Scilex Holding (SCLX) Convertible Debt (2021 - 2022) Analysis & Trends
Scilex Holding's Convertible Debt history runs 2 years deep, the most recent figure standing at $2.0 million for Q3 2022.
- In Q3 2022, Convertible Debt changed N/A year-over-year to $2.0 million; the TTM figure through Sep 2022 stood at $2.0 million (changed N/A YoY), while the FY2021 annual figure was $483099.0, changed N/A from the prior year.
- Convertible Debt for Q3 2022 stood at $2.0 million, roughly flat from $2.0 million in the prior quarter.
- The five-year high for Convertible Debt was $2.0 million in Q3 2022, with the low at $483099.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.49 Bn | 632.73 Bn | 17.26 Bn |
| 2 | AbbVie | 470.91 Bn | 464.34 Bn | 12.70 Bn |
| 3 | Merck | 379.63 Bn | 372.49 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.40 Bn | 253.50 Bn | 12.86 Bn |
| 6 | Amgen | 237.10 Bn | 223.11 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.02 Bn | 179.84 Bn | 6.22 Bn |
| 8 | Pfizer | 161.60 Bn | 149.90 Bn | 10.94 Bn |
| 9 | Gsk | 105.86 Bn | 101.70 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.18 Mn | -73.61 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.04 Mn |
| Jun 30, 2022 | 2.03 Mn |
| Mar 31, 2022 | 2.03 Mn |
| Dec 31, 2021 | 483,099.00 |